3,4-Dihydro-5H-2,3-benzodiazepine derivatives and pharmaceutical use thereof
US4423044A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Feb 25, 1982 |
| Grant date | Dec 27, 1983 |
| Priority date | — |
| Expiry date | Feb 25, 2002 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to new 3,4-dihydro-5H-2,3-benzodiazepine derivatives of general formula (I) and pharmaceutically acceptable acid addition salts thereof, ##STR1## wherein R represents a phenyl group optionally carrying one or two substituents selected from the group consisting of halogen, hydroxy, C.sub.1-4 alkoxy and benzyloxy; a furyl or a thienyl group, PA0 R.sup.1 stands for a hydrogen atom or a C.sub.1-4 alkyl group, PA0 R.sup.2 and R.sup.3 each represent hydrogen atom, C.sub.1-4 alkoxy, C.sub.4-7 cycloalkoxy or benzyloxy group. The new compounds of the general formula (I) can be prepared by reducing a 5H-2,3-benzodiazepine derivative of the general formula (II) ##STR2## wherein R, R.sup.1, R.sup.2 and R.sup.3 have the above-defined meanings, with an inorganic or organic hydride and/or complex metal hydride. The new compounds of the general formula (I) possess significant central nervous effects and can advantageously be used in the therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.